1. Home
  2. KELYA vs GLSI Comparison

KELYA vs GLSI Comparison

Compare KELYA & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kelly Services Inc.

KELYA

Kelly Services Inc.

HOLD

Current Price

$9.66

Market Cap

334.9M

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$27.82

Market Cap

372.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KELYA
GLSI
Founded
1946
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
334.9M
372.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
KELYA
GLSI
Price
$9.66
$27.82
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$15.00
$50.00
AVG Volume (30 Days)
561.0K
195.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.12
N/A
Revenue Next Year
$2.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.98
$7.78
52 Week High
$14.94
$34.10

Technical Indicators

Market Signals
Indicator
KELYA
GLSI
Relative Strength Index (RSI) 46.66 55.41
Support Level $8.28 $9.47
Resistance Level $10.68 $32.61
Average True Range (ATR) 0.54 2.47
MACD -0.12 -0.37
Stochastic Oscillator 28.10 72.83

Price Performance

Historical Comparison
KELYA
GLSI

About KELYA Kelly Services Inc.

Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: